Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medical Countermeasures: Long-Term Funding Could Spur More Development Work

Executive Summary

Chimerix CEO tells Congress allocating Project Bioshield a multi-year funding stream would provide more long-term certainty for countermeasure sponsors.

You may also be interested in...



Outgoing Merck CEO Touts COVID Innovations, But Worries Pandemic Prep May Lack Staying Power

Ken Frazier says advocates need to ensure governments continue investing in global biosecurity.

Biodefense Bill Moving In Senate; Still Debate Over Best Approach For Flu

US Pandemic and All Hazards Preparedness Act appears on track for on-time reauthorization – but there may still be debate over whether and how to dedicate funding specifically for pandemic flu preparedness and stockpiling.

Drug Shortage Legislation Possible As US FDA Seeks New Powers To Prevent Problems

Commissioner Gottlieb proposes new authorities that could require manufacturers of certain drugs to establish risk mitigation plans to avert potential drug shortages.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS123244

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel